Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility and cost-effectiveness?

James Cook University Hospital0 个研究点目标入组 107 人开始时间: 2017年8月15日最近更新: 2021年1月25日

试验速览

•1. Adults (=18 years) who are clinically considered to be candidates for SCS as per NICE TA159
•2. Pain of neuropathic nature of an intensity of at least 5 as assessed on a numerical rating scale (NRS)
•3. Patient has persistent pain for more than 6 months despite appropriate conventional medical and surgical management including (TENS), acupuncture, oral analgesic agents, cognitive behavioural therapy as well as nerve blockade where appropriate
•4. Satisfactory multidisciplinary assessment by a team with expertise in delivering SCS therapy
•5. Capable of providing informed consent

•1. Patient refusal to participate in the study
•2. Presence of an on-going pain condition considered by the investigator to overshadow the neuropathic pain condition to be treated with SCS
•3. Current or previous treatment with an implanted pain relief device
•4. Current participation or planned participation in other studies that may confound the results of this study
•5. Ongoing anticoagulation therapy, which cannot be safely discontinued
•6. Poor cognitive ability
•7. Unable to undergo study assessments or complete questionnaires independently
•8. Patient is pregnant or planning to become pregnant during the course of the study

发起方

James Cook University Hospital